Neuropeptide S (NPS) as a Treatment for Anxiety, Sleep Disorders, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, and Asthma
Tech ID: 18857 / UC Case 2004-053-0
Patent "WO02/31145" discloses a newly deorphanized GPCR system, Neuropeptide S (NPS), the endogenous ligand, and its cognate GPCR. However this patent does not detail the pharmacological or physiological function of NPS and its GPCR. University of California, Irvine researchers have characterized NPS's function in the CNS.
University of California, Irvine researchers have shown that central administration of NPS increases locomotor activity in mice and decreases paradoxical (REM) sleep and slow wave sleep in rats. NPS was further shown to produce anxiolytic-like effects in mice exposed to different stressful paradigms.
The NPS receptor may be used as a system to assay for agonists that are useful therapeutic agents in narcolepsy, hypersomnia or under conditions when elevated alertness is required. Antagonists to the NPS receptor may also be assayed for novel therapeutic approach to treat insomnia. NPS may also be used in the treatment or prevention of asthma and it also may be used as a therapeutic in Attention Deficit Hyperactivity Disorder (ADHD) and Attention Deficit Disorder (ADD).
|United States Of America||Published Application||20100056455||03/04/2010||2004-053|
ADHD, Sleep disorders
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- Platelet Aggregation Inhibitors
- ADP Glucose Receptor as a Target for Disorders Involving Platelet Aggregation
- New Chemical Entities for the Treatment and Prevention of Diabetes and Metabolic Disorders
- Gaba Receptor Antagonist Selective For Gabarho Receptors
- Prokineticin 2 and Prokineticin Receptor 2: Therapeutic Target for Anxiety and Mood Disorders